Skip to main content

Advertisement

SpringerLink
Log in

Clinical trials in rheumatoid arthritis: a status report from the ClinicalTrials.gov website

  • Short Communication
  • Published:
Rheumatology International Aims and scope Submit manuscript

Abstract

The aims of this study are to describe the characteristics of clinical trials in rheumatoid arthritis (RA) listed in ClinicalTrials.gov and examine existing trends in study design, funding sources, outcomes, and drugs under investigation. We conducted a survey of ongoing clinical trials in RA registered in the ClinicalTrials.gov website. We used the advanced search option and applied the following inclusion criteria, “rheumatoid arthritis”, “open studies”, “interventional”, and “adults 18 years or older”. Of 127 eligible trials, 53.5% of the studies were either phase 3 or 4, and 40.2% were phase 1, 2, and 2/3. Two-thirds of the trials were randomized (70.9%), and over half were, in addition, double-blinded (53.5%) and placebo-controlled (53.5%). Universities were listed as the primary sponsor for 18.9% of the trials and pharmaceutical industry for 73.2%. Majority of the trials were multi-center studies (93%) conducted outside the United States (54.3%). The most frequently used endpoint was drug efficacy (54.3%) followed by drug safety (25.2%). Most industry-funded trials were open for less than 12 months, whereas most university-funded trials were open for more than 24 months (58% each). Biologic therapies were the focus of most trials in the registry (78.5%). Randomized, double-blinded, placebo-controlled, phase 3 and 4 trials form the majority of ongoing clinical trials in RA. The preponderance of industry funding of RA trials and the short duration of such trials are troubling trends which need to be addressed.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Hootman J, Bolen J, Helmick C, Langmaid G (2006) Prevalence of doctor-diagnosed arthritis and arthritis-attributable activity limitation—United States, 2003–2005. MMWR 55(40):1089–1092

    Google Scholar 

  2. Myasoedova E, Crowson CS, Kremers HM, Therneau TM, Gabriel SE (2010) Is the incidence of rheumatoid arthritis rising? Results from Olmsted County, Minnesota, 1955–2007. Arthritis Rheum 62(6):1576–1582

    Article  PubMed  Google Scholar 

  3. van Vollenhoven RF (2009) Treatment of rheumatoid arthritis: state of the art 2009. Nat Rev Rheumatol 5:531–541

    Article  PubMed  Google Scholar 

  4. DeAngelis CD, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R (2004) International committee of medical journal editors. Clinical trial registration: a statement from the international committee of medical journal editors. JAMA 292:1363–1364

    Article  PubMed  CAS  Google Scholar 

  5. Schulz KF, Altman DG, Moher D, CONSORT Group (2010) CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 63(8):834–840

    Article  PubMed  Google Scholar 

  6. Harris RP, Helfand M, Woolf SH, Lohr KN, Mulrow CD, Teutsch SM et al (2010) Methods work group, third US preventive services task force. Current methods of the US preventive services task force: a review of the process. Am J Prev Med 3(Suppl):21–35

    Google Scholar 

  7. Bourgeois FT, Murthy S, Mandl KD (2010) Outcome reporting among drug trials registered in ClinicalTrials.gov. Ann Intern Med 153(3):158–166

    PubMed  Google Scholar 

  8. Lexchin J, Bero LA, Djulbegovic B, Clark O (2003) Pharmaceutical industry sponsorship and research outcome and quality: systematic review. BMJ 326:1167–1170

    Article  PubMed  Google Scholar 

  9. Bathon JM, Martin RW, Fleischmann RM, Tesser JR, Schiff MH, Keystone EC et al (2000) A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 343(22):1586–1593

    Article  PubMed  CAS  Google Scholar 

  10. Maini R, St Clair EW, Breedveld F, Furst D, Kalden J, Weisman M et al (1999) Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT study group. Lancet 354(9194):1932–1939

    Article  PubMed  CAS  Google Scholar 

  11. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD et al (2001) Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 345(15):1098–1104

    Article  PubMed  CAS  Google Scholar 

  12. Recommendations for Regulatory Action for Rosiglitazone and Rosiglitazone containing Products (NDA 21-071, supplement 035, incoming submission dated August 25, 2009)—9/12/2010. Gerald J. Dal Pan, MD, MHS, Director, Office of Surveillance and Epidemiology, Federal Drug Administration

  13. Van der Kooij SM, le Cessie S, Goekoop-Ruiterman YPM, de Vries-Bouwstra JK, van Zeben D, Kerstens PJSM (2009) Clinical and radiological efficacy of initial versus delayed treatment with infliximab plus methotrexate in patients with early rheumatoid arthritis. Ann Rheum Dis 68(7):1153–1158

    Article  PubMed  Google Scholar 

  14. St Clair EW, van der Heijde DM, Smolen JS, Maini RN, Bathon JM, Emery P et al (2004) Combination of infliximab and methotrexate therapy for early rheumatoid arthritis: a randomized, controlled trial. Arthritis Rheum 50(11):3432–3443

    Article  PubMed  CAS  Google Scholar 

  15. Breedveld FC, Weisman MH, Kavanaugh AF, Cohen SB, Pavelka K, Vollenhoven R et al (2006) The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 54:26–37

    Google Scholar 

  16. Emery P, Breedveld FC, Hall S, Durez P, Chang DJ, Robertson D et al (2008) Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active, early, moderate to severe rheumatoid arthritis (COMET): a randomised, double-blind, parallel treatment trial. Lancet 372:375–382

    Google Scholar 

  17. Tak PP, Rigby WF, Rubbert-Roth A, Peterfy CG, van Vollenhoven RF, Stohl W et al (2010) For the IMAGE investigators. Extended report: inhibition of joint damage and improved clinical outcomes with rituximab plus methotrexate in early active rheumatoid arthritis: the IMAGE trial. Ann Rheum Dis. (annrheumdis 137703: Published Online First: 11 October 2010)

  18. Wolfe F, Cathey MA (1991) The assessment and prediction of functional disability in rheumatoid arthritis. J Rheumatol 18(9):1298–1306

    PubMed  CAS  Google Scholar 

  19. Hulsmans HM, Jacobs JW, van der Heijde DM, van Albada-Kuipers GA, Schenk Y, Bijlsma JW (2000) The course of radiologic damage during the first six years of rheumatoid arthritis. Arthritis Rheum 43(9):1927–1940

    Article  PubMed  CAS  Google Scholar 

  20. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. New Eng J Med 340:253–259

    Article  PubMed  CAS  Google Scholar 

  21. Weinblatt ME, Keystone EC, Furst DE, Moreland LW, Weisman MH, Birbara CA et al (2003) Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial. Arthritis Rheum 48:35–45

    Article  PubMed  CAS  Google Scholar 

  22. Kremer JM, Westhovens R, Leon M, Di Giorgio E, Alten R, Steinfeld S et al (2003) Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. New Eng J Med 349:1907–1915

    Article  PubMed  CAS  Google Scholar 

  23. Peto R, Baigent C (1998) Trials: the next 50 years. Large scale randomized evidence of moderate benefits. BMJ 317(7167):1170

    Article  PubMed  CAS  Google Scholar 

  24. Miller JD (2010) Registering clinical trial results: the next step. JAMA 303:773–774

    Article  PubMed  CAS  Google Scholar 

  25. O’Connor AB (2009) The need for improved access to FDA reviews. JAMA 302:191–193

    Article  PubMed  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Medicine, St. Luke’s Hospital, St. Louis, MO, USA

    Jisna R. Paul

  2. Division of Rheumatology, Washington University School of Medicine, 660 S. Euclid, Box 8045, St Louis, MO, 63110, USA

    Prabha Ranganathan

Authors
  1. Jisna R. Paul
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Prabha Ranganathan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Prabha Ranganathan.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Paul, J.R., Ranganathan, P. Clinical trials in rheumatoid arthritis: a status report from the ClinicalTrials.gov website. Rheumatol Int 32, 1831–1835 (2012). https://doi.org/10.1007/s00296-011-2027-3

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00296-011-2027-3

Keywords

Search

Navigation